These papers are retrospective reviews and did not require ethics committee approval.

MLB has received honoraria from Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB, grants and/or speaker for Abiogen, Alexion, Amgen, Bruno Farmaceutici, Echolight, Eli Lilly, Kyowa Kirin, SPA, Theramex, UCB, consultant for Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB. AAK has received research grants from Alexion, Amgen, Ascendis, Chugai, Radius, Takeda, Ultragenyx and is on the advisory board for Amgen, Amolyt, and Takeda. ETR has consulted for, received honoraria from, and has research supported by Alexion Pharmaceuticals and AstraZeneca Rare Disease. SB has received advisory board participation from Alexion. KMD has received research grants and honoraria from Alexion. CD serves as an investigator, consultant, and speaker for Amgen; investigator for Radius; speaker for Alexion. SWI has received grant funding, ad hoc advisory board participation from Alexion Pharmaceuticals. MKJ has received honoraria and grants from UCB, Amgen, Kyowa Kirin, Sanofi, Besin Healthcare, AbbVie. RK is a speaker and has received research funding from Alexion, AstraZeneca Rare Disease. EML serves as an investigator, consultant, and speaker for Amgen; investigator for Radius; speaker for Alexion. AL is a consultant for and has received research funding and honoraria from Alexion. MEN serves as a non-paid consultant (fee equivalent donated to 501(c)3 patient advocacy groups) for Alexion. CR-G is a member of the Scientific Advisory Board of the HPP Global Patient Registry sponsored by Alexion AstraZeneca Rare Disease. She has had received honoraria for participation on this Board and has also received honoraria for select Alexion-sponsored presentations. CR has received research grants and honoraria from Alexion, Kyowa Kirin, Regeneron. LS has received honoraria and grants from Alexion, Amgen, Chiesi, KyowaKirin, Novartis, Theramex, UCB. JHS serves as an Investigator and consultant for Alexion. SRS has received honoraria from and has research supported by Alexion Pharmaceuticals, AstraZeneca Rare Disease. LMW serves as a consultant to Alexion. DSA, HA-A, KA, FA, KD, SLF, FG, GG, EH, SK, IM, FM, LY, and RB-P declare that they have no conflict of interest.